Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
| 09/30/2018 | 06/30/2018 | 03/31/2018 | 12/31/2017 | 09/30/2017 | |
|---|---|---|---|---|---|
| Net Income | -30.55% | 59.84% | 46.61% | -63.61% | 1.23% |
| Total Depreciation and Amortization | -8.82% | -4.23% | -11.25% | -27.27% | 103.70% |
| Total Amortization of Deferred Charges | 30.93% | 33.33% | 39.37% | 1,714.29% | -- |
| Total Other Non-Cash Items | 0.00% | -2.33% | -66.67% | -62.82% | 114.20% |
| Change in Net Operating Assets | 37.47% | -50.57% | -192.01% | -15.04% | 2.42% |
| Cash from Operations | 19.11% | 38.15% | 4.26% | -270.19% | 38.02% |
| Capital Expenditure | -450.00% | 0.00% | 97.80% | -468.75% | -45.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -450.00% | 0.00% | 97.80% | -468.75% | -45.45% |
| Total Debt Issued | 0.00% | -36.48% | 363.29% | -93.23% | 58,462.50% |
| Total Debt Repaid | 27.91% | -19.44% | 92.65% | 81.23% | -1,584.52% |
| Issuance of Common Stock | -- | -- | -- | -41.38% | -65.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.35% | -37.89% | 821.21% | -108.33% | 210.72% |
| Foreign Exchange rate Adjustments | 94.29% | -25.00% | -106.64% | 261.69% | -294.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.39% | 32.10% | 84.63% | -196.58% | 1,060.99% |
